Vitro Biopharma, Inc.

For fiscal year 2025 ending October 31, 2025, the company reported total revenue of $2.1 million with a gross profit of $1.6 million. However, the company incurred significant operating losses, with a loss from operations of $5.0 million and a net loss of $10.9 million. The net loss available to common stockholders was $10.9 million, resulting in a net loss per common share of $2.00 (basic and diluted). The company's balance sheet shows total assets of $4.9 million, but total liabilities of $21.3 million resulted in a stockholders' deficit of $16.3 million. Cash flow from operations was negative $2.5 million, while financing activities provided $2.6 million, resulting in a net cash increase of $33,000 during the period. The company's financial position reflects significant debt obligations and derivative liabilities totaling $21.3 million, with current liabilities exceeding current assets by $4.8 million.

Key Takeaways